Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium Review uri icon


MeSH Major

  • Blast Crisis
  • Hematopoietic Stem Cell Transplantation
  • Leukemia, Myeloid, Acute
  • Myeloablative Agonists
  • Myeloproliferative Disorders


  • Leukemic transformation (LT) of a myeloproliferative neoplasm (MPN) is associated with a dismal prognosis and no medical therapies have shown a survival improvement in patients with MPN in blast phase (MPN-BP). Effective therapies for the treatment of MPN-BP are a serious unmet need. Consensus response criteria do not exist for the treatment of patients with MPN-BP and this is necessary for the uniformed reporting of treatment response in clinical trials. We have identified relevant MPN and MPN-BP features in order to define treatment response categories that reflect hematological, clinical, pathological, cytogenetic and molecular changes after therapeutic intervention. We plan to validate these proposed response criteria within multi-centered clinical trials.

publication date

  • December 2012



  • Review



  • eng

PubMed Central ID

  • PMC4114151

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2012.08.013

PubMed ID

  • 22938832

Additional Document Info

start page

  • 1500

end page

  • 4


  • 36


  • 12